Startups
The company will be helmed by Jes Olesen, the former president of the European Federation of Neurological Societies and chairman of the Danish Headache Center.
Each year, BioSpace evaluates biotech startups for the last year and applies an algorithm that includes funding, collaboration, the state of their pipeline and editorial awards for innovation.
Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.
One entity will focus on pharmaceuticals and drug development, while the other will be aimed at consumer healthcare.
It plans to launch a new, independent, publicly-traded company to handle those products. No name for the new company has been announced.
“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement,” said Satish Jindal, BioMotiv’s chief executive officer.
The new entity, funded by $55 million from the BCBS businesses, was born as a response to the high costs of prescription medicines in the United States and concerns about the overall affordability of health care.
With a massive $200 million Series A financing round, EQRx launches with the mission of creating novel medicines that are more affordable for patients and more sustainable for healthcare systems.
Roivant Sciences, helmed by biotech billionaire Vivek Ramaswamy, launched a new subsidiary, Lokavant, a technology company with the important mission of ensuring that no clinical trial fails due to operational error.
Tyra Biosciences, based in Carlsbad, California, closed on a Series A financing worth $50 million.
PRESS RELEASES